Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Me's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control ...

Regeneron acquires bankrupt 23andMe for $256M. What this DNA data sale means for privacy, pharma, and your genetic ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...

Regeneron Pharmaceuticals has announced that it will be acquiring human genetics and biotechnology company 23andMe for $256m.

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Alert: Your DNA Is At Risk in This New Age of Increased Surveillance** The recent sale of the genetic data company 23andMe to Regeneron Pharmaceuticals has raised significant concerns about the ...

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm ...

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, ...